Related Experiment Video
Updated: Jul 4, 2026

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
Intratracheal administration of third-generation lentivirus vector encoding MPT51 from Mycobacterium tuberculosis
Dai Hashimoto1, Toshi Nagata, Masato Uchijima
1Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Higashi-ku, Handa-yama, Hamamatsu 431-3192, Japan.
Abstract:
The present study evaluates the potential of improved third-generation lentivirus vector with respect to their use as an in vivo-administered T-cell vaccine against tuberculosis. Intratracheal administration of the lentivirus vector encoding MPT51 of Mycobacterium tuberculosis could induce MPT51-specific CD8+ T cells in the mediastinal lymph nodes 2 weeks after the administration. The vaccination could generate MPT51-specific memory CD8+ T cells in the lung, but not in the lymph nodes. Further, a single intratracheal immunization of MPT51 lentiviral vaccine decreased significantly the number of virulent M. tuberculosis in the lung after intratracheal challenge of the bacillus. These findings suggest that intratracheal immunization of the third-generation lentiviral vaccines is a promising vaccination strategy against pulmonary tuberculosis.
Related Concept Videos
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Tuberculosis
